{"id":2896,"date":"2019-08-23T06:00:00","date_gmt":"2019-08-23T06:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/"},"modified":"2019-08-23T06:00:00","modified_gmt":"2019-08-23T06:00:00","slug":"lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/","title":{"rendered":"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center"},"content":{"rendered":"
Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), has purchased an XVIVO Perfusion System (XPS\u2122) with STEEN Solution\u2122 Perfusate to use in its new ex vivo lung perfusion (EVLP) center in Jacksonville, Florida. Lung Bioengineering previously purchased an XPS\u2122 to use in its EVLP center in Silver Spring, Maryland in 2018. The aim of the new EVLP center in Jacksonville is to reduce the shortage of transplantable lungs through the use of a centralized organ evaluation service.<\/strong><\/div>\n

Lung Bioengineering purchased an XVIVO Perfusion System (XPS\u2122) with STEEN Solution Perfusate from XVIVO Perfusion AB (STO: XVIVO) for use in its Jacksonville Ex Vivo Lung Perfusion (EVLP) center. XVIVO Perfusion will continue to provide training and supplies for use of their machines by transplant hospitals to re-evaluate donated lungs that have initially been deemed unsuitable for transplant. Lung Bioengineering and XVIVO Perfusion will also continue to cooperate and collaborate in promoting the use of centralized XPS EVLP services that could increase the supply of transplantable lungs to address needless patient deaths on the transplant waitlist. <\/span><\/p>\n

On April 26, 2019 XVIVO received Premarket approval (PMA) from the FDA for XPS with STEEN Solution Perfusate for sale on the American market. The XPS with STEEN Solution Perfusate was the first medical device that was approved for EVLP of initially unacceptable donated lungs.<\/span><\/p>\n

\u201cWe are very pleased that the collaboration agreement is extended to Lung Bioengineering\u00b4s new Jacksonville facility. United Therapeutics\u2019 impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages,\u201d said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion. <\/span><\/p>\n

August 23, 2019
<\/span>Magnus Nilsson
Gothenburg
XVIVO Perfusion AB (publ)<\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 am CET on August 23, 2019.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), has purchased an XVIVO Perfusion System (XPS\u2122) with STEEN…<\/p>\n","protected":false},"template":"","class_list":["post-2896","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-ci"],"acf":[],"yoast_head":"\nLung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), has purchased an XVIVO Perfusion System (XPS\u2122) with STEEN...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\\\/\",\"name\":\"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2019-08-23T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/","og_locale":"en_US","og_type":"article","og_title":"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center - XVIVO","og_description":"Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), has purchased an XVIVO Perfusion System (XPS\u2122) with STEEN...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/","name":"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2019-08-23T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lung-bioengineering-has-acquired-the-xps-for-use-in-its-new-jacksonville-evlp-center\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Lung Bioengineering has acquired the XPS\u2122 for use in its new Jacksonville EVLP center"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}